Edwards Lifesciences Stock | Price, Analyst Rating & Outlook for 2026

Edwards Lifesciences

NYSE:EW

$ 86,19

+ $0,41 (0,48%)

86,19 $

+$0,41 (0,48%)

End-of-day quote: 12/05/2025

Edwards Lifesciences Stock Value

The analyst rating for NYSE:EW is currently Outperform.

Outperform

Edwards Lifesciences Company Info

EPS Growth 5Y

5,49%

Market Cap

$49,78 B

Long-Term Debt

$0,60 B

Short Interest

1,95%

Annual earnings

02/13/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

1958

Industry

Health Care

Country

United States

ISIN Number

US28176E1082

Website

https://www.edwards.com

Analyst Price Target

$95,00

10.22%

Last Update: 12/06/2025

Analysts: 28

Highest Price Target $105,00

Average Price Target $95,00

Lowest Price Target $84,00

In the last five quarters, Edwards Lifesciences’s Price Target has fallen from $97,51 to $96,55 - a -0,98% decrease. Thirty Two analysts predict that Edwards Lifesciences’s share price will increase in the coming year, reaching $95,00. This would represent an increase of 10,22%.

Top growth stocks in the health care sector (5Y.)

What does Edwards Lifesciences do?

Edwards Lifesciences Corporation (Edwards Lifesciences) operates as a global structural heart innovation company, driven by a passion to improve patient lives. The company conducts operations worldwide and is managed in the following geographical regions: United States, Europe, Japan, and Rest of World. Edwards Lifesciences focuses on technologies that treat structural heart disease. The products and technologies provided by Edwards Lifesciences are categorized into the following main groups: T...

Edwards Lifesciences Corporation (Edwards Lifesciences) operates as a global structural heart innovation company, driven by a passion to improve patient lives.

The company conducts operations worldwide and is managed in the following geographical regions: United States, Europe, Japan, and Rest of World. Edwards Lifesciences focuses on technologies that treat structural heart disease. The products and technologies provided by Edwards Lifesciences are categorized into the following main groups: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical).

The company's work encompasses both surgical and transcatheter therapies. In addition, the company's unique portfolio of repair and replacement technologies for both mitral and tricuspid heart valves that provides a broad set of treatment options to serve the many diverse and complex patients in need. Edwards remains committed to its strategy of transformative product innovation, robust and expanding clinical evidence to support approvals and adoption, as well as comprehensive support to ensure excellent real-world patient outcomes.

Cardiovascular disease is the number-one cause of death in the world and is the top disease in terms of health care spending in nearly every country. In the U.S. alone, one cardiovascular patient dies every 33 seconds. Cardiovascular disease is progressive in that it tends to worsen over time and often affects the structure of an individual's heart.

Patients undergoing treatment for cardiovascular disease can be treated with a number of the company’s medical technologies, which are designed to address individual patient needs with respect to disease process, comorbidities, and health status.

Edwards Lifesciences' Product and Technology Offerings

The company’s products are categorized into the following groups: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical).

Transcatheter Aortic Valve Replacement

The company is the global leader in transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves, including the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating patients who have severe symptomatic aortic stenosis. The SAPIEN 3 valves are delivered while the heart is still beating. The majority of procedures are conducted without the use of general anesthesia and patients are discharged home within one to two days. Transcatheter aortic valve replacement with the SAPIEN 3 family of valves enables patients to recover more quickly and return to a better quality of life sooner than patients receiving traditional open heart surgical therapies. Edwards' transcatheter aortic heart valves were first commercialized in Europe in 2007, in the United States in 2011, and in Japan in 2013. Edwards has partnered with the physician community to generate optimistic data that has expanded access to patients of all risk profiles. In 2024, EARLY TAVR trial data were presented, demonstrating the superiority of early TAVR intervention in severe asymptomatic aortic stenosis patients with the SAPIEN 3 platform versus clinical surveillance. The SAPIEN 3 platform remains the only transcatheter heart valve with a THV-in-THV indication for patients assessed at high risk for surgical replacement, offering patients the ability to have a second minimally invasive procedure. The SAPIEN family of valves is the most widely implanted transcatheter heart valves in the world, with over one million patient lives impacted since launch. Additionally, the Edwards SAPIEN 3 system and Alterra system offer a minimally invasive option for pulmonary valve replacement for patients with congenital heart disease.

Sales of the company’s TAVR products represented 75% of net sales in 2024.

Transcatheter Mitral and Tricuspid Therapies

The company continues to make significant investments in the development of transcatheter heart valve repair and replacement technologies designed to treat mitral and tricuspid valve diseases. While several technologies are in the development and clinical phases, the PASCAL Precision transcatheter repair system (in Europe, the United States, and Japan), EVOQUE tricuspid valve replacement system (in Europe and the United States), and Cardioband tricuspid valve reconstruction system (in Europe) are commercially available. The PASCAL Precision system addresses the needs of patients with mitral or tricuspid regurgitation through leaflet approximation, while the Cardioband system enables clinicians to reduce the size of a valve's annulus to lower regurgitation. The EVOQUE system, the world's first transcatheter tricuspid valve replacement therapy to receive regulatory approval, addresses tricuspid valve regurgitation by replacing the native valve with a bioprosthetic valve. The SAPIEN M3 transcatheter mitral valve replacement system is based on the proven SAPIEN valve and is designed specifically for mitral patients.

Surgical Structural Heart

The company continues to invest in bringing innovations to cardiac surgery patients. The company's RESILIA tissue, with published clinical data showing 99% freedom from structural valve deterioration through seven years, has set the new standard for tissue valve durability. The flagship INSPIRIS RESILIA aortic valve offers RESILIA tissue and VFit technology. INSPIRIS is the leading aortic surgical valve in the world. Sales of the company's surgical therapies in the United States also continue to gain traction with KONECT RESILIA, the first pre-assembled, ready-to-implant, tissue valved conduit for complex combined procedures.

The company's latest innovation, the MITRIS RESILIA valve, is commercially available in the United States, Europe, and Japan, as well as other geographies, where it has been widely adopted by surgeons as the leading product in the company's mitral valve portfolio.

Sales of the company’s surgical tissue heart valve products represented 18% of the company’s net sales in 2024.

Competition

In TAVR, the company's primary competitors include Medtronic plc (Medtronic), Abbott Laboratories (Abbott), and Boston Scientific Corporation. In TMTT, the company's primary competitor is Abbott, and there are a considerable number of large and small companies with development efforts in these fields. In Surgical, the company's primary competitors include Medtronic, Abbott, and Artivion, Inc.

Sales and Marketing

The company's portfolio includes some of the most recognizable cardiovascular device product brands in treating structural heart disease today. The company has a number of product lines that require sales and marketing strategies tailored to deliver high-quality, cost-effective products and technologies to customers worldwide. Because of the diverse global needs of the population that it serves, the company's distribution system consists of several direct sales forces as well as independent distributors.

To achieve optimal outcomes for patients, the company conducts educational symposia and best practices training for its physician, hospital executive, service line leadership, nursing, and clinical-based customers. The company relies extensively on its sales and field clinical specialist personnel who work closely with its customers in hospitals. Field clinical specialists routinely attend procedures where Edwards' products are being used in order to provide guidance on the use of the company's devices, thereby enabling physicians and staff to reach expert proficiency and deliver positive patient outcomes. In addition to working closely with physicians, nurses, and other clinical personnel, the company's customers include decision-makers such as service line leaders, material managers, biomedical staff, hospital administrators and executives, purchasing managers, and ministries of health. Also, for certain of the company's product lines and where appropriate, its corporate sales team actively pursues approval of Edwards Lifesciences as a qualified supplier for hospital group purchasing organizations (GPOs) that negotiate contracts with suppliers of medical products. Additionally, the company has contracts with a number of United States and European national and regional buying groups, including healthcare systems and Integrated Delivery Networks. Where the company chooses to market its products is also influenced by the existence of, or potential for, adequate reimbursement to hospitals and other providers by national healthcare systems.

United States: In the United States, the company sells substantially all of its products through its direct sales forces. In 2024, 59% of the company’s net sales were derived from sales to customers in the United States.

Outside of the United States: In 2024, 41% of the company’s net sales were derived outside of the United States through its direct sales forces and independent distributors. Of the total sales outside of the United States, 59% were in Europe, 15% were in Japan, and 26% were in Rest of World. The company sells its products in approximately 100 countries, including Japan, Germany, France, United Kingdom, Italy, China, and Canada. A majority of the sales and marketing approach outside of the United States is direct sales, although it varies depending on each country's size and state of development.

Government Regulation and Other Matters

The company’s products and facilities are subject to regulation by numerous government agencies, including the FDA, European Union member states competent authorities, and the Japanese Pharmaceuticals and Medical Devices Agency. These entities confirm its compliance with the various laws and regulations governing the development, testing, manufacturing, labeling, marketing, and distribution of its products.

The company is also subject to additional laws and regulations that govern its business operations, products, and technologies, including federal, state, and foreign anti-kickback laws and regulations, which generally prohibit payments to anyone, including physicians as an inducement to purchase or recommend a product; the Stark law, which prohibits physicians from referring Medicare or Medicaid patients to a provider that bills these programs for the provision of certain designated health services if the physician (or a member of the physician's immediate family) has a financial relationship with that provider; federal and state laws and regulations that protect the confidentiality of certain patient health information, including patient records, and restrict the use and disclosure of such information, in particular, the Health Insurance Portability and Accountability Act of 1996; the Physician Payments Sunshine Act, which requires public disclosure of the financial relationships of United States physicians and teaching hospitals with applicable manufacturers, including medical device, pharmaceutical, and biologics companies; the False Claims Act, which prohibits the submission of false or otherwise improper claims for payment to a federally funded health care program, and health care fraud statutes that prohibit false statements and improper claims to any third-party payor; and the United States Foreign Corrupt Practices Act, which can be used to prosecute United States companies for arrangements with foreign government officials or other parties, or for not keeping accurate financial records or maintaining adequate internal controls to prevent and detect arrangements with foreign government officials or other parties.

In Europe, the company’s products are subject to extensive regulatory requirements.

The delivery of the company’s products is subject to regulation by the United States Department of Health and Human Services (HHS) and comparable state and foreign agencies responsible for reimbursement and regulation of health care items and services.

Seasonality

The company’s quarterly sales are influenced by many factors, including new product introductions, acquisitions, regulatory approvals, patient and physician holiday schedules, and other factors. Sales in the third quarter (year ended December 31, 2024) are typically lower than other quarters of the year due to the seasonality of the United States and European markets, where summer vacation schedules normally result in fewer medical procedures.

Dispositions

On September 3, 2024, the company sold its Critical Care product group (Critical Care).

History

Edwards Lifesciences Corporation was founded in 1958. The company was incorporated in 1999.

Edwards Lifesciences Questions and Answers

Which sectors generate sales and which are the top 3 markets?

Main industries: Heart valve products Critical care technologies Surgical heart valves TOP 3 markets and their percentage shares (estimated for 2025): USA: approx. 55% Europe: approx. 25% Asia-Pacific: approx. 15% Edwards Lifesciences Corporation generates the majority of its revenue from the sa...

At which locations are the company’s products manufactured?

Production sites of Edwards Lifesciences Corporation: Irvine, California, USA Draper, Utah, USA Anasco, Puerto Rico Cartago, Costa Rica Singapore Edwards Lifesciences Corporation is a leading company in the field of heart valve and hemodynamic monitoring technologies. The production facilities are...

What strategy does Edwards Lifesciences pursue for future growth?

Revenue Growth: Estimated 8-10% annually (2025) Focus on Innovation: Edwards Lifesciences Corporation is strongly focused on developing new technologies in the field of heart valve therapies. The company continuously invests in research and development to expand its product range and offer innovativ...

Which raw materials are imported and from which countries?

Main raw materials: Silicone, polyurethane, stainless steel, titanium Countries of origin: USA, Germany, China, Japan Edwards Lifesciences Corporation is a leading company in the production of heart valves and hemodynamic monitoring systems. The production of these medical devices requires specific...

How strong is the company’s competitive advantage?

Market share in heart valves: 60% (2024) Research & Development (R&D) expenses: 17% of revenue (2024) Patent portfolio: Over 2,000 patents worldwide (2024) Edwards Lifesciences Corporation has a significant competitive advantage, especially in the field of heart valve technology. With a mark...

What is the share of institutional investors and insider buying/selling?

Institutional investor share: approx. 85% (estimated for 2025 based on historical data) Insider purchases/sales: No significant transactions in the last months (estimated for 2025) The institutional investor share at Edwards Lifesciences Corporation is traditionally high, as the company operates in...

What percentage market share does Edwards Lifesciences have?

Market share of Edwards Lifesciences: 25% (2025, estimated) Main competitors and their market shares: Medtronic: 30% Abbott Laboratories: 20% Boston Scientific: 15% Johnson & Johnson: 7% Terumo Corporation: 3% Moat of Edwards Lifesciences: Edwards Lifesciences has a significant moat, mainly ba...

Is Edwards Lifesciences stock currently a good investment?

Revenue Growth: 10% (2024) Profit Growth: 8% (2024) Research & Development Expenses: 17% of revenue (2024) Edwards Lifesciences Corporation recorded a revenue growth of 10% in 2024, attributed to strong demand for its innovative heart valve products. The company also achieved a profit growth of...

Does Edwards Lifesciences pay a dividend – and how reliable is the payout?

Dividend: No payout (2025) Edwards Lifesciences Corporation traditionally does not pay a dividend. The company has focused on reinvesting its profits in research and development as well as strategic acquisitions to strengthen its market position in the field of heart valves and cardiovascular techno...

Edwards Lifesciences Stock Value

Edwards Lifesciences Company Info

Analyst Price Target

Top growth stocks in the health care sector (5Y.)

What does Edwards Lifesciences do?

Edwards Lifesciences Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal